Anupam Rasayan Targets 60–70% Bliss Utilization, EPS Accretive

Anupam Rasayan India Limited — Q4 FY26 Earnings Call (May 25, 2026)

1. Overall Tone of Management: Optimistic

• Management repeatedly emphasizes “highest ever revenue,” “remain confident,” “positive on our growth trajectory,” and “we remain positive/confident in long-term growth outlook.”
• They provide multiple integration and utilization upside narratives (e.g., Bliss utilization “30%… can be very quickly enhanced to 60% to 70%”) and explicitly state “EPS accretive from day 1.”

2. Key Themes from Management Commentary

• Diversification into higher-value chemistries & pharma
• High-performance materials and pharma growth called out strongly: high-performance materials “threefold” (FY22 INR97cr → FY26 INR305cr) and pharma “15-fold” (FY22 INR21cr → FY26 INR339cr).
• Agro dependence reduced from “76%… in FY ’22 to 55% in FY ’26,” framed as improving “demand visibility” and “resilience.”
• Backward integration / supply chain control
• Tanfac acquisition framed as securing “uninterrupted access” to critical raw materials (HF, KF) and improving “cost competitiveness” and “supply chain visibility.”
• M&A as platform-building across the value chain
• Jayhawk: U.S. footprint + advanced custom synthesis; synergy benefits expected to be more visible in FY27 because only “1 month and 2 days” were consolidated in FY26.
• Bliss GVS Pharma: definitive agreement to acquire 43.3%–48.2% + open offer; positioned as creating an integrated pharma platform (KSM → finished dosage) and leveraging regulated-market approvals.
• Capital discipline / capex completion
• FY26 capex: “INR315 crores… last leg of the capex program,” with “all our plants are commercialized.”
• Near-term stance: “We are not envisaging any major capex in near future.”
• Working capital improvement as a core performance lever
• Operating cash flow: “INR334 crores” in FY26, attributed to “improved asset utilization… better working capital management.”
• Expectation to continue improving working capital into FY27.

3. Q&A Analysis

Theme A: Rationale, governance, and structure of Bliss acquisition

• Core questions
• Why acquire Bliss? Will current management continue?
• Will Bliss be merged/delisted or kept independent?
• Transaction structure and funding; EPS accretion; timeline for benefits.
• Management response
• Rationale: build a “full pharma platform” (KSM to finished dosage) and leverage Anupam’s pharma end-market focus; also cite Bliss’s low utilization.
• Governance: “current management shall continue” and they will “work with the same team.”
• Independence: “no” merger/delisting; “keep them independent and run as an independent entity.”
• Funding: “INR300 crores via NCDs” + balance via “non-consolidating non-voting… quasi-equity” to maintain control/consolidation.
• EPS: “EPS accretive from day 1.”
• Utilization upside: Bliss “30%… can be very quickly enhanced to 60% to 70%.”
• Notable / evasive / strong points
• Strong confidence on utilization and EPS accretion, but limited quantified synergy economics.
• On Bliss-specific product scope (CDMO/FDF details), management deflects: “Let us wait… inappropriate… today.”

Theme B: Growth trajectory, order book conversion, and visibility

• Core questions
• Expected pro forma revenue/EBITDA after consolidation of all entities.
• Base business growth excluding Jayhawk; evolving mix (pharma/polymer vs agro).
• How much growth is organic vs acquisition synergies.
• Management response
• Pro forma: Anupam ~INR1,676cr; Tanfac INR711cr; Jayhawk INR722cr; Bliss INR927cr → “over INR 4,000 crores” revenue and “EBITDA… around INR834 crores.”
• Base growth: stand-alone growth “20% to 25% or 30%… CAGR” over 3–5 years; FY26 stand-alone growth “over 60% to 70%.”
• Visibility: order book “INR14,000 crores”; incremental annual revenue from pipeline “INR1,700 to INR1,800 crores” (part agro, part polymer).
• Synergies: Jayhawk/Bliss “on top of it.”
• Notable / evasive / strong points
• Mix/margin guidance is cautious on ramp-up products (see Theme C), but growth confidence is high.

Theme C: Margins, working capital, and cash conversion

• Core questions
• Will pharma/polymer be margin accretive vs agro?
• Working capital trajectory given mix shift; targets for working capital days.
• Debt repayment schedule and interest cost.
• Management response
• Margin: management says they’ll “continue… FY26 margin” range; acknowledges “upward bias” but refuses to guide due to ramping products: “I do not want to guide… ramping up products.”
• Working capital: pro forma consolidated working capital “215 to 220-odd days”; excluding Jayhawk “240 to 250 days.”
• Debt/interest: gross debt ~INR1,500cr; net ~INR1,100cr; working-capital-heavy; argues comfort via EBITDA coverage.
• Tax rate: guided “around about 25%” (standalone).
• Notable / evasive / strong points
• Clear refusal to provide forward margin guidance beyond “blended” comfort range due to ramp-up uncertainty.
• Working capital targets were more specific than margins (e.g., working capital days trajectory).

Theme D: Bliss operational details (CDMO scope, API vs FDF, customer overlap)

• Core questions
• If Bliss doesn’t make API, how will synergy work?
• Are there common customers across Bliss/Jayhawk/Anupam?
• Geographic exposure (Africa) and integration approach (duplication vs independence).
• Management response
• Synergy framed mainly on FDF vertical integration and CDMO projects; also leverage regulated-market approvals and existing CDMO projects.
• Customer overlap acknowledged: “few customers… overlap and cross-pollination.”
• Africa exposure: Anupam “no exposure”; Bliss “yes… largely there.”
• Integration philosophy: “integration does not mean… bring it into 1 corporate entity”; plants remain separate.
• Notable / evasive / strong points
• On CDMO being “finished formulations,” management again deflects: “Let us wait… inappropriate… on behalf of Bliss management.”

4. Guidance / Outlook

Explicit guidance (quantitative)

• Capex
• FY26 capex: “INR315 crores”
• Near-term: “not envisaging any major capex in near future”
• Maintenance capex (standalone): “INR50-odd crores” (range “INR50 crores to INR75 crores”)
• Working capital days
• Pro forma consolidated: “215 to 220-odd days”
• Standalone (excluding Jayhawk): “240 to 250 days”
• FY27 target (from Q&A): “below 200… around 180 days or below”
• Growth targets
• Stand-alone CAGR aspiration: “20% to 25% or 30%… over next 3 to 5 years”
• Debt / interest
• Interest cost (medium term not fully quantified, but near-term implied): earlier in call “INR650 crores of EBITDA… comfortable” (coverage argument)
• Tax rate (standalone): “around about 25%”

Implicit signals (qualitative)

• Synergy timing: Bliss synergies “start playing out over near to medium term,” with CDMO expansion results in “6 to 12 months” and larger benefits by “18 months.”
• Margin stance: management is comfortable with FY26 blended EBITDA margin range but avoids detailed forward margin guidance due to ramp-up uncertainty.
• Integration approach: emphasizes “independent entity” model (no merger/delisting), suggesting lower integration execution risk but potentially slower synergy capture.

5. Standout Statements (direct / revealing)

• Utilization upside (Bliss): “30%… can be very quickly enhanced to 60% to 70% in the near to medium term.”
• EPS claim: “EPS accretive from day 1.”
• Independence of Bliss: “no… keep them independent and run as an independent entity.”
• Capex completion / no near-term growth capex: “all our plants are commercialized. We are not envisaging any major capex in near future.”
• Working capital confidence: “trajectory… very, very encouraging” and expects continued improvement.
• Margin guidance restraint: “I do not want to guide… ramping up products” (signals uncertainty in forward margin profile).
• Integration philosophy: “integration does not mean that I need to bring it into 1 corporate entity.”

6. Red Flags / Positive Signals

Positive signals
– Strong cash generation narrative: “operating cash flow of INR334 crores” and operating cash conversion emphasis.
– Clear capital discipline: capex program completed; maintenance capex quantified.
– Working capital improvement quantified with day targets and pro forma ranges.

Red flags
– Overconfident synergy claims without quantified economics (utilization jump, EPS accretion) while refusing to guide margins due to ramp-up uncertainty.
– Deflection on Bliss operational specifics (CDMO scope, FDF vs other details) repeatedly: “Let us wait… inappropriate.”
– Margin guidance ambiguity: management says pharma/polymer should be margin accretive but won’t provide forward margin numbers beyond “FY26 range.”

7. Historical Comparison & Consistency Analysis

a. Change in Tone Over Time

• Current (Q4 FY26): more “deal/platform” heavy; confident about multiple acquisitions (Jayhawk already, Bliss pending) and long-term growth.
• Prior (Q3 9MFY26, Feb 14 2026): optimistic but more focused on execution of order book and Jayhawk integration; less on a new large acquisition.
• Shift classification: More Optimistic
• Language has moved from “optimistic growth momentum” to “landmark year,” “highest ever revenue,” and strong acquisition-driven upside (utilization 60–70%, EPS accretive day 1).

b. Tracking Past Commitments vs Outcomes

• Working capital improvement targets (earlier calls)
• Prior (Q2/H1 FY26, Oct 17 2025): expected working capital days reduction to “200 days in near term” and FY27 “below 200… ~180 days” was later echoed in Q3 call.
• Current (Q4 FY26): pro forma consolidated “215–220 days” and FY27 “below 200… around 180 days.”
• Assessment: ✅ On track qualitatively; exact day targets are slightly higher in pro forma now, but FY27 target is reiterated.
• Jayhawk integration timing
• Prior (Q3 FY26, Feb 14 2026): Jayhawk acquisition expected to close “in coming weeks” and EPS accretive from day one.
• Current: FY26 includes only “1 month and 2 days,” and synergy visibility “more visible going forward in FY27.”
• Assessment: ✅ Delivered in accounting sense (partial consolidation), ⏳ Synergy visibility delayed to FY27 (explicitly acknowledged).
• Elementium LOI / revenue contribution
• Prior (Q2/H1 FY26, Oct 17 2025): Elementium LOI discussed; no meaningful revenue from Elementium LOI was stated in Q2 call.
• Current: no new Elementium update; focus shifted to Bliss/Jayhawk/Tanfac.
• Assessment: ⏳ Not progressed in narrative (dropped from emphasis).

c. Narrative Shifts

• From “inventory liquidation + working capital turnaround” (Q2/Q1 FY26) to “platform acquisitions + integration synergies” (Q4 FY26).
• Agro recovery was a major theme in Q1/Q2/Q3 (demand normalization, channel inventory), but in Q4 it’s more of a background while pharma/performance materials and acquisitions dominate.
• Margin guidance has become more cautious: earlier calls provided margin stabilization ranges; now they avoid forward margin guidance due to ramp-up products.

d. Consistency & Credibility Signals

• Credibility: Medium
• Strength: management provides concrete operational/cash metrics (OCF, capex completion, working capital days).
• Weakness: repeated high-confidence synergy outcomes (utilization jump, EPS accretion day 1) paired with limited quantified proof and selective deflection on Bliss operational details.
• Pattern: when asked for forward-looking financial precision (margins, product scope), management becomes non-committal.

e. Evolution of Key Themes

• Demand / macro: earlier calls emphasized macro recovery and agro demand normalization; current call emphasizes portfolio mix + acquisitions.
• Margins: stable blended margin narrative persists, but forward margin precision has reduced (“don’t want to guide”).
• Expansion / integration: integration narrative expanded from Tanfac → Jayhawk → now Bliss, with a consistent “independent entity + cross-leverage” model.
• Working capital: remains a consistent theme, with increasingly specific day targets.

f. Additional Insights (Cross-Period Intelligence)

• The company’s cash generation story is strengthening (OCF INR334cr in FY26), but margin guidance is less forthcoming—suggesting that while cash conversion is improving, profitability may depend on ramp-up execution and acquisition integration timing.
• The repeated “independent entity” stance for acquisitions may reduce execution complexity, but it also implies synergies may be slower/less controllable, consistent with management’s own “near to medium term” and FY27 visibility language.